GMI News

GMI Announces Two Appointments to Its Board

By March 31, 2017 No Comments

kari-stefansson-paul-saundersDr. Kari Stefansson and Dr. Paul Saunders Appointed to the Board

Irish life sciences company Genomics Medicine Ireland Ltd., has today announced the appointment of Dr. Kari Stefansson and Dr. Paul Saunders to its Board of Directors. The appointment will increase the size of the Genomics Medicine Ireland Board of Directors to six members.
“We are delighted to have Kari Stefansson and Paul Saunders join our Board of Directors,” said Daniel Crowley, acting CEO, Genomics Medicine Ireland. Dr. Stefansson, a luminary in the field of genetics, is founder and CEO of deCODE genetics, a groundbreaking genetics company now part of Amgen. Paul Saunders leads the Innovation and Special Investments group at GMI investor, ISIF (Ireland Strategic Investment Fund). “Genomics Medicine Ireland will benefit greatly from the insight and expertise Drs. Stefansson and Saunders bring to our board,” said Crowley

With this appointment, the Genomics Medicine Ireland Board of Directors now consists of Daniel Crowley, Paul Thurk, Co-founder of GMI and Managing Director of ARCH Venture Partners Europe, Tom Hulme, General Partner at GV (formerly Google Ventures), Terry McGuire, Founding Partner at Polaris Partners, Paul Saunders, Ireland Strategic Investment Fund and Kari Stefansson, deCODE genetics.


Kári Stefánsson

Kári Stefánsson, M.D., Dr. Med. founded deCODE genetics in August 1996. He was previously a professor of Neurology, Neuropathology and Neuroscience at Harvard University and Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. He has shaped deCODE’s scientific approach and been actively engaged in leading its gene discovery work, serving as senior author on most of the company’s publications in major scientific journals. deCODE is now part of Amgen, a founding corporate partner to GMI.
Paul Saunders

Paul Saunders is Head of Innovation and Special Investments for the Ireland Strategic Investment Fund, leading the sovereign fund’s investment agenda targeting large, transformative ‘Big Idea’ opportunities. Prior to joining the fund, Paul worked as Head of Innovation for An Post, as Group Development Director for Greencore, Bioenergy Development Director for NTR and as Senior Consultant with McKinsey and Co in Dublin and London. Paul has a BSc in Physics from Bristol University, a PhD in Physics from Cambridge University and an MBA from Insead.